In addition, DLBCL-activated FRCs (DLBCL-FRCs) inhibited CD8+ TIL cytolytic activity via aberrant expression of PD-1 ligands (PD-L1 and PD-L2). The gene discussed is PDCD1LG2; the disease is diffuse large B-cell lymphoma.